SUCLG2-AS1 has been proposed as a prognostic marker for triple-negative breast cancer and ccRCC, despite the fact that the mechanism by which it affects tumor development remains unknown (Wu et al., 2021; Yang et al., 2021). Here, SUCLG2 is linked to nonpapillary renal cell carcinoma.